<?xml version="1.0" encoding="UTF-8"?>
<p id="Par49">A DNA plasmid-based vaccine targeting S protein of the SARS-CoV-2 (INO-4800) has been developed by INOVIO Pharmaceuticals and reported to induce immune cells activation via intradermal inoculation [
 <xref ref-type="bibr" rid="CR209">209</xref>, 
 <xref ref-type="bibr" rid="CR216">216</xref>]. Moreover, the generation of cell-mediated and humoral immune responses in mice and guinea pigs were reported post-immunization with INO-4800 during pre-clinical studies along with the induction of specific neutralizing antibodies [
 <xref ref-type="bibr" rid="CR216">216</xref>]. The phase 1 clinical trial of the INO-4800 reported its safety and well-tolerability in all volunteers along with stimulation of immune response in 94% of the volunteers against the SARS-CoV-2 after completion of phase 1 clinical trial [
 <xref ref-type="bibr" rid="CR217">217</xref>].
</p>
